← Leaderboards
Susan Manzi
University Of Pittsburgh At Pittsburgh
$6,430,165
Attributed
$6,430,165
Total exposure
14
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $782K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$6,430,165 · 14
By mechanism
R01$4,926,518 · 1
K24$1,302,218 · 1
P60$114,169 · 1
M01$87,260 · 11
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Alejandro Jose Almarza$7,341,242
- Juan Manuel Taboas$2,227,654
- Nam V Vo$9,841,127
- Gwendolyn A Sowa$4,670,730
- Roy A Mariuzza$20,943,458
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusHuman SubjectClinical ResearchFemaleHuman Therapy EvaluationInflammationClinical TrialsUltrasonographyMyocardial InfarctionMedical ComplicationWomen'S HealthClinical Trial Phase IDrug Screening /EvaluationPathologic ProcessDisease /Disorder Proneness /RiskPatient Oriented ResearchCardiovascular Disorder RiskHormone Regulation /Control MechanismAutoimmune DiseasesComplementComplement ActivationAtherosclerosisCardiovascular DiseasesAging
Grant awards (59)
Vascular Disease in Systemic Lupus Erythematosus$148,824
K24 · FY2011 · AR · contact PI
Progression of Cardiovascular Disease in Lupus.$414,302
R01 · FY2010 · AR · contact PI
Vascular Disease in Systemic Lupus Erythematosus$148,824
K24 · FY2010 · AR · contact PI
Progression of Cardiovascular Disease in Lupus.$562,967
R01 · FY2009 · AR · contact PI
Vascular Disease in Systemic Lupus Erythematosus$148,824
K24 · FY2009 · AR · contact PI
Progression of Cardiovascular Disease in Lupus.$606,105
R01 · FY2008 · AR · contact PI
Vascular Disease in Systemic Lupus Erythematosus$148,824
K24 · FY2008 · AR · contact PI
Progression of Cardiovascular Disease in Lupus.$633,133
R01 · FY2007 · AR · contact PI
Vascular Disease in Systemic Lupus Erythematosus$148,824
K24 · FY2007 · AR · contact PI
Progression of Cardiovascular Disease in Lupus.$641,736
R01 · FY2006 · AR · contact PI
VASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS$116,695
K24 · FY2005 · AR
HEARTS: HEART EFFECTS ON ATHEROSCLEROSIS/RISKS OF THROMBOSIS IN SLE$28,647
M01 · FY2005 · RR
Epidemiology of Systemic Lupus &Cardiovascular Disease$511,424
R01 · FY2004 · AR
VASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS$114,083
K24 · FY2004 · AR
Heart Effects on Atherosclerosis/Risks of Thrombosis$34,341
M01 · FY2004 · RR
Epidemiology of Systemic Lupus &Cardiovascular Disease$528,848
R01 · FY2003 · AR
VASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS$111,546
K24 · FY2003 · AR
Epidemiology of Systemic Lupus &Cardiovascular Disease$511,160
R01 · FY2002 · AR
VASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS$109,082
K24 · FY2002 · AR
EFFECT OF DOXYCYCLINE ON OSTEOARTHRITIS PROGRESSION$0
M01 · FY2002 · RR
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN LUPUS WOMEN$0
M01 · FY2002 · RR
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN LUPUS WOMEN$0
M01 · FY2002 · RR
MULTICENTER CONTROLLED STUDY OF DHEA FEMALE PATIENTS WITH ACTIVE SLE$0
M01 · FY2002 · RR
MULTICENTER CONTROLLED STUDY OF DHEA FEMALE PATIENTS WITH ACTIVE SLE$0
M01 · FY2002 · RR
MULTICENTER DOUBLE BLIND TRIAL OF LJP394 IN PATIENTS WITH SLE KIDNEY NEPHRITIS$0
M01 · FY2002 · RR
MULTICENTER DOUBLE BLIND TRIAL OF LJP394 IN PATIENTS WITH SLE KIDNEY NEPHRITIS$0
M01 · FY2002 · RR
MENSTRUAL CYCLING &DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
MENSTRUAL CYCLING &DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
OPEN LABEL MULTICENTER EVALUATE LONG TERM SAFETY DHEA IN PTS W/ SLE$0
M01 · FY2002 · RR
OPEN LABEL MULTICENTER EVALUATE LONG TERM SAFETY DHEA IN PTS W/ SLE$0
M01 · FY2002 · RR
HORMONE REPLACEMENT IN POSTMENOPAUSAL WOMEN W/ SLE$0
M01 · FY2002 · RR
HORMONE REPLACEMENT IN POSTMENOPAUSAL WOMEN W/ SLE$0
M01 · FY2002 · RR
EFFECT OF DOXYCYCLINE ON OSTEOARTHRITIS PROGRESSION$0
M01 · FY2002 · RR
LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
BG9588 IN PROLIFERATIVE LUPUS GLOMERULONEPHRITIS$0
M01 · FY2002 · RR
BG9588 IN PROLIFERATIVE LUPUS GLOMERULONEPHRITIS$0
M01 · FY2002 · RR
Epidemiology of Systemic Lupus &Cardiovascular Disease$516,843
R01 · FY2001 · AR
VASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS$106,692
K24 · FY2001 · AR
EFFECT OF DOXYCYCLINE ON OSTEOARTHRITIS PROGRESSION$0
M01 · FY2001 · RR
BG9588 IN PROLIFERATIVE LUPUS GLOMERULONEPHRITIS$0
M01 · FY2001 · RR
MULTICENTER DOUBLE BLIND TRIAL OF LJP394 IN PATIENTS WITH SLE KIDNEY NEPHRITIS$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN LUPUS WOMEN$0
M01 · FY2001 · RR
MULTICENTER CONTROLLED STUDY OF DHEA FEMALE PATIENTS WITH ACTIVE SLE$0
M01 · FY2001 · RR
LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
HORMONE REPLACEMENT IN POSTMENOPAUSAL WOMEN W/ SLE$0
M01 · FY2001 · RR
OPEN LABEL MULTICENTER EVALUATE LONG TERM SAFETY DHEA IN PTS W/ SLE$0
M01 · FY2001 · RR
MENSTRUAL CYCLING &DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
MENSTRUAL CYCLING AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)$114,169
P60 · FY2000 · AR
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN LUPUS WOMEN$3,034
M01 · FY2000 · RR
MENSTRUAL CYCLING &DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS$3,034
M01 · FY2000 · RR
MULTICENTER DOUBLE BLIND TRIAL OF LJP394 IN PATIENTS WITH SLE KIDNEY NEPHRITIS$3,034
M01 · FY2000 · RR
MULTICENTER CONTROLLED STUDY OF DHEA FEMALE PATIENTS WITH ACTIVE SLE$3,034
M01 · FY2000 · RR
HORMONE REPLACEMENT IN POSTMENOPAUSAL WOMEN W/ SLE$3,034
M01 · FY2000 · RR
OPEN LABEL MULTICENTER EVALUATE LONG TERM SAFETY DHEA IN PTS W/ SLE$3,034
M01 · FY2000 · RR
EFFECT OF DOXYCYCLINE ON OSTEOARTHRITIS PROGRESSION$3,034
M01 · FY2000 · RR
EFFECTS OF DMP777 ON JOINT MANIFESTION IN PTS W/ SLE$3,034
M01 · FY2000 · RR
BG9588 IN PROLIFERATIVE LUPUS GLOMERULONEPHRITIS$0
M01 · FY2000 · RR
LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR